Koninklijke Bibliotheek, National Library of the Netherlands
IP1491214186496
Metastatic neuroendocrine tumor with initial presentation of orbital apex syndrome
Huang, Yen-Yu
Chang, Anna
Chou, Yuh-Yu
Hsu, Wei-Chih
text
article
monographic
Interdisciplinary neurosurgery : advanced techniques and case management
continuing
22147519
0000000013588
7
C
text
Born digital tijdschriften
KB collectiekavel
text
Elektronische Wetenschappelijke Tijdschriften
EWTIJ
10.1016/j.inat.2016.10.009
urn:nbn:nl:kb-1491214186240
Automatisch gegenereerd op basis van de EWTIJ XML in release 1.5 van het digitaal magazijn.
INAT
151
S2214-7519(16)30095-0
10.1016/j.inat.2016.10.009
The Authors
Fig. 1
Coronal contrast and noncontrast T1 weighted images (A, B), axial contrast T1 weighted image (C), and axial T2 weighted image (D). These pictures showed the heterogeneous soft tissues within the orbital apex, extending to orbital canal and cavernous sinus (arrows).
Fig. 1
Fig. 2
The tumor tissue composed of large polygonal cells with hyperchromatic nuclei, distinct nucleoli and moderate pink cytoplasm (H&E stain, 400×).
Fig. 2
Fig. 3
Positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-d-glucose integrated with computed tomography (18F-FDG PET/CT) showed intense uptake in left retro-orbital region and paranasal sinus. The intense uptake also involved the spine, rib cage, pelvic bones, bilateral femora and both lobes of liver.
Fig. 3
Case Report & Case Series
Metastatic neuroendocrine tumor with initial presentation of orbital apex syndrome
Yen-Yu
Huang
a
Anna
Chang
a
Yuh-Yu
Chou
b
Wei-Chih
Hsu
a
c
⁎
m002006@ms.skh.org.tw
a
Department of Neurology, Shin-Kong WHS Memorial Hospital,Taipei, Taiwan
Department of Neurology
Shin-Kong WHS Memorial Hospital
Taipei
Taiwan
b
Department of Pathology, Shin-Kong WHS Memorial Hospital,Taipei, Taiwan
Department of Pathology
Shin-Kong WHS Memorial Hospital
Taipei
Taiwan
c
Department of Medicine, Fu-Jen Catholic University,New Taipei City, Taiwan
Department of Medicine
Fu-Jen Catholic University
New Taipei City
Taiwan
⁎
Corresponding author at: 95 Wen-Chang Road, Shin-Lin District, Taipei, Taiwan.
95 Wen-Chang Road
Shin-Lin District
Taipei
Taiwan
Abstract
The possible etiologies of orbital apex syndrome range from inflammatory, infectious, neoplastic, iatrogenic/traumatic, to vascular processes. In patients without obvious infection or systemic cancer history, judicious use of corticosteroids is a reasonable strategy. We describe a 64-year-old man who presented with orbital apex syndrome and had progressed to total visual loss in three days after admission. Radiological imaging and pathological studies were consistent with a neuroendocrine tumor with multiple metastases. We recommend that a biopsy-proven specimen is warranted in patient with orbital apex syndrome even without a cancer history.
Highlights
•
The etiologies of orbital apex syndrome are broad and the adequate management depends on the exact diagnosis.
•
The use of corticosteroids is reasonable in patients without obvious infection and cancer history.
•
Obtaining a biopsy-proven evidence is warranted in patients with orbital apex syndrome.
•
Searching for possible primary origin or systemic metastases is important in patients with neuroendocrine tumors.
Keywords
Orbital apex syndrome
Neuroendocrine tumor
Corticosteroids
1
Introduction
Lesions affecting the anatomically adjacent structures, including optic nerve (II), oculomotor nerve (III), trochlear nerve (IV), abducens nerve (VI), ophthalmic/maxillary branch of the trigeminal nerve (V1, V2) and oculosympathetic fibers, may cause three partially overlapping clinical syndromes: superior orbital fissure, orbital apex, and cavernous sinus syndrome. The etiologies causing these syndromes are also quite similar, i.e., inflammatory, infectious, neoplastic, iatrogenic/traumatic, or vascular processes. Based on the broad spectrum of etiologies, the decision on evaluation and management remains a great challenge to clinical physicians [1]. For example, the use of corticosteroids is warranted for inflammatory process, but may be harmful to some infection etiologies. Also, conservative measures may be adequate for some causes, whereas urgent procedures are necessary in others.
Possible primary tumors involving the orbital apex and cavernous sinus include lymphoma, neural tumors and local invasion from adjacent head and neck tumors. The metastatic tumors include the origins from breast, lung, kidney and malignant melanoma. Some inflammatory causes, like orbital pseudotumor, Tolosa-Hunt syndrome, and thyroid orbitopathy, may mimic neoplasms [1–3]. Among the neoplasms, neuroendocrine tumor is relatively rare and usually arises from gastrointestinal tract or bronchopulmonary source [4]. Here, we reported a rare case of high grade neuroendocrine tumor of unknown primary site with initial presentation of progressive ptosis and vision loss as orbital apex syndrome, which highlighted the importance of obtaining biopsy-proven specimen in such patients.
2
Case report
A 64-year-old man was previously healthy and was referred to neurological clinic for ptosis in the left eye. He had acute onset of ptosis, retro-orbital soreness and mild blurred vision on the left side for one month. There was no double vision and motor or sensory symptoms. There was also no fever, rhinorrhea, nose stuffy, and tinnitus. The orbital symptoms had progressed gradually without obvious diurnal change. Neurologic examinations showed left ptosis, mild palpebral swelling without erythematous change, sluggish light reflex and slight upper ward gaze limitation in the left eye. The visual acuity was 6/10 in the right eye and 6/12 in the left eye on the day of admission. The symptom had progressed rapidly within three days that there was no light perception and full dilated pupil without light reflex in his left eye. The laboratory tests for inflammation and infection, including complete blood count with differential count, erythrocyte sedimentation rate, C-reactive protein, were normal. The serologic studies, including liver and renal function, along with carcinoembryonic antigen and alpha-fetoprotein, were also normal. The acetylcholine receptor antibody was within normal range. The magnetic resonance imaging of brain revealed a prominent left cavernous sinus with increasing soft tissue component that anteriorly extended into the orbital cavity, and heterogeneous enhancement in the retrobulbar space. Trace enhancements in the intracavernous and retrobulbar spaces were also depicted (Fig.1
). He underwent sphenoethomoidectomy, and a dark reddish tumor was found at the opticocarotid recess. The pathology of the tumor showed large polygonal cells with hyperchromatic nuclei, distinct nucleoli and moderate pink cytoplasm (Fig. 2
), and immunoreactivity to several immunohistochemical stainings, including cytokeratin, neuron-specific enolase, synaptophysin and chromogranin A, which were compatible with a neuroendocrine tumor. Positron emission tomography/computed tomography (PET/CT) scan showed increased multiple uptakes at the left orbital area, spines, rib cages and liver (Fig.3
). Echo-guided liver biopsy revealed the same high grade malignant tumor with neuroendocrine differentiation. The primary site of the tumor was unclear. The patient died six months after initial symptoms.
3
Discussion
The orbital apex tumors range from benign inflammatory process to high grade malignancy. Ocular symptom is the initial manifestation of metastatic orbital tumors in up to 25% [5]. The diagnosis may be difficult in patients without history of systemic cancers. Neuroendocrine tumors are rare among the metastatic orbital tumors, and the clinical manifestation may masquerade cellulitis [2] or Graves orthopathy [3]. Furthermore, metastases are found in about 20% of the patients with neuroendocrine tumors at the time of diagnosis [6]. Similar to our patient but with a different scenario, a patient was reported previously with an unknown origin of neuroendocrine tumor in liver and was found to have orbital metastasis on both sides six month later [7].
When the cause of orbital apex is unable to be determined, possible management options include observation, an empirical trial of corticosteroid, and surgical biopsy. Because the distinctions among inflammation, infection, and neoplasm are often difficult and all may respond initially to corticosteroids, a short period of therapeutic corticosteroid trial has been suggested in the patients without systemic signs of infection or cancer history [1]. Because of the acute onset of symptoms with rapid progression that seemed to be more typical of an inflammatory process, a trial of corticosteroid was considered and used. After excluding the possibility of a vascular source by images and obtaining sufficient support of biopsy technique, a fine needle biopsy was considered at first. Because of rapidly loss of vision, however, sphenoethomoidectomy was done for the additional purpose of decompression. Without the tissue proof, the strategy of corticosteroid use may delay the diagnosis and further management in our patient.
From this experience, we recommend that a tissue proof may need to be considered first if the surgical risk is not high or the vision loss or ophthalmalgia is progressing rapidly. Pathological evidence is crucial for the diagnosis in patients with orbital apex syndrome, and an immunohistochemistry study may be helpful in identifying a neuroendocrine origin. When the neuroendocrine tumor is confirmed, further investigations of primary origin and possible systemic metastases are mandatory.
Conflicts of interest/disclosures
The authors declare that they have no financial or other conflicts of interest in relation to this research and its publication.
References
[1]
S.
Yeh
R.
Foroozan
Orbital apex syndrome
Curr. Opin. Ophthalmol.
15
2004
490
498
[2]
A.
Atik
M.
Krilis
K.
Shannon
Small cell neuroendocrine carcinoma masquerading as cellulitis and causing blindness via bilateral orbital involvement
Orbit
32
2013
197
199
[3]
M.
Sira
R.P.
Clauss
C.
Maclean
G.E.
Rose
Orbital metastases from neuroendocrine carcinoma, masquerading as graves orbitopathy
Orbit
29
2010
94
96
[4]
D.J.
Shetlar
R.L.
Font
N.
Ordonez
A.
el-Naggar
M.
Boniuk
A clinicopathologic study of three carcinoid tumors metastatic to the orbit. Immunohistochemical, ultrastructural, and DNA flow cytometric studies
Ophthalmology
97
1990
257
264
[5]
R.A.
Goldberg
J.
Rootman
Clinical characteristics of metastatic orbital tumors
Ophthalmology
97
1990
620
624
[6]
H.
Kang
J.B.
O'Connell
M.J.
Leonardi
Rare tumors of the colon and rectum: a national review
Int. J. Color. Dis.
22
2007
183
189
[7]
V.
Sivagnanavel
P.
Riordan-Eva
J.
Jarosz
P.
Portmann
M.
Buxton-Thomas
Bilateral orbital metastases from a neuroendocrine tumor
Neuro-Ophthalmology
24
2004
240
242
INAT
151
S2214-7519(16)30095-0
10.1016/j.inat.2016.10.009
The Authors
Case Report & Case Series
Metastatic neuroendocrine tumor with initial presentation of orbital apex syndrome
Yen-Yu
Huang
a
Anna
Chang
a
Yuh-Yu
Chou
b
Wei-Chih
Hsu
a
c
⁎
m002006@ms.skh.org.tw
a
Department of Neurology, Shin-Kong WHS Memorial Hospital,Taipei, Taiwan
Department of Neurology
Shin-Kong WHS Memorial Hospital
Taipei
Taiwan
b
Department of Pathology, Shin-Kong WHS Memorial Hospital,Taipei, Taiwan
Department of Pathology
Shin-Kong WHS Memorial Hospital
Taipei
Taiwan
c
Department of Medicine, Fu-Jen Catholic University,New Taipei City, Taiwan
Department of Medicine
Fu-Jen Catholic University
New Taipei City
Taiwan
⁎
Corresponding author at: 95 Wen-Chang Road, Shin-Lin District, Taipei, Taiwan.
95 Wen-Chang Road
Shin-Lin District
Taipei
Taiwan
Abstract
The possible etiologies of orbital apex syndrome range from inflammatory, infectious, neoplastic, iatrogenic/traumatic, to vascular processes. In patients without obvious infection or systemic cancer history, judicious use of corticosteroids is a reasonable strategy. We describe a 64-year-old man who presented with orbital apex syndrome and had progressed to total visual loss in three days after admission. Radiological imaging and pathological studies were consistent with a neuroendocrine tumor with multiple metastases. We recommend that a biopsy-proven specimen is warranted in patient with orbital apex syndrome even without a cancer history.
Highlights
•
The etiologies of orbital apex syndrome are broad and the adequate management depends on the exact diagnosis.
•
The use of corticosteroids is reasonable in patients without obvious infection and cancer history.
•
Obtaining a biopsy-proven evidence is warranted in patients with orbital apex syndrome.
•
Searching for possible primary origin or systemic metastases is important in patients with neuroendocrine tumors.
Keywords
Orbital apex syndrome
Neuroendocrine tumor
Corticosteroids
KBJ00000000006166
2017-04-01T23:22:01
S300.2
S300
S2214-7519(16)30095-0
10.1016/j.inat.2016.10.009
INAT
2214-7519
151
CRP
NON-CRC
UNLIMITED
NONE
2016-10-27T16:11:15Z
22147519/v7sC/S2214751916300950/main.xml
21997
MAIN
JA 5.4.0 ARTICLE
FULL-TEXT
22147519/v7sC/S2214751916300950/main.assets/gr1.sml
27743
IMAGE-THUMBNAIL
22147519/v7sC/S2214751916300950/main.assets/gr2.sml
47198
IMAGE-THUMBNAIL
22147519/v7sC/S2214751916300950/main.assets/gr3.sml
16336
IMAGE-THUMBNAIL
22147519/v7sC/S2214751916300950/main.assets/gr1.jpg
101787
IMAGE-DOWNSAMPLED
22147519/v7sC/S2214751916300950/main.assets/gr2.jpg
82115
IMAGE-DOWNSAMPLED
22147519/v7sC/S2214751916300950/main.assets/gr3.jpg
26165
IMAGE-DOWNSAMPLED
22147519/v7sC/S2214751916300950/main.pdf
707876
MAIN
1.7 6.5
DISTILLED OPTIMIZED BOOKMARKED
22147519/v7sC/S2214751916300950/main.raw
10295
S2214-7519(16)X0005-9
INAT
2214-7519
7
C
201703
1
78
S2214-7519(16)30095-0
10.1016/j.inat.2016.10.009
9
11
main.pdf
PDF
1.7
local
1491214186240
collectiebehoudsniveau 1
2017-04-03T10:41:49.407+02:00
local
1491214186752
0
SHA-512
862554596a5307bb777263a8405e2bd2ac8b099478bafeed71ff5600c187028e13d4465b335208d82834417c079b0b46b44ff6648304233c084ae40dda20b187
java.security.MessageDigest
12394
not checked
metadata.xml
local
1491214186753
0
SHA-512
68b32b7ccb92ed3b850b2eca54d8fe0a5658ef65252a16eac7d2ec29d872b8b174b46f231434ba16e9c57637672e9fca698757a5be074dd1353b0d34d071cdca
java.security.MessageDigest
27743
not checked
gr1.sml
local
1491214186754
0
SHA-512
df1e2d094b73e313cde4b38a15f3ed2702adabced4d1d029ab7370b7b2a6ed3a3c1a72c05533f8c490bf11da14a9e7da64b90f9b39d55836de1d2e26c43a7f24
java.security.MessageDigest
82115
not checked
gr2.jpg
local
1491214186755
0
SHA-512
9083afe2274babf06e8d3437332a67c812e4a830e4be3e11a42ae71115a95a5bf26ba3803fb0e2f06ce59ba4140ff11ff7a6e514b88533d32e2d15efc2fb361d
java.security.MessageDigest
26165
not checked
gr3.jpg
local
1491214186756
0
SHA-512
72d7e600691e97f59755c8dd30f9c9f465f3b3e316b303671ab4eb264f2752af24b9666fafc46e56dcc4bff01d0d1cffe86a2bab1ee91b79b759e7692a3bc7c3
java.security.MessageDigest
101787
not checked
gr1.jpg
local
1491214186757
0
SHA-512
358b0e8b2557d5f3ec8dfb5de400a74a3cff094c6a1c49e03a6eacc1ffd73fa4b009cbbcc8261d1e39292e7fc50117a8530770b3f4ed249fa2a3019b6fe79791
java.security.MessageDigest
47198
not checked
gr2.sml
local
1491214186758
0
SHA-512
2f7dec36f60e2ce9a0fc1d50e6d456de65add8434fdf935e15c546ed3e2b758b4fe545a40fdde903df34e690229d0628b017ae6ca89b305078c0aa8c9864ad0b
java.security.MessageDigest
16336
not checked
gr3.sml
local
1491214186759
0
SHA-512
ba0e527cecbc071a5e6bad27e126935890b25bc0c4b4fa3c6c38c9285962a802b3724ff1147cef3574c134402d839d6bf81d6bf2a0c9fb8a693f58afb6caf61e
java.security.MessageDigest
10295
not checked
main.raw
local
1491214186760
0
SHA-512
da3f1a8c20f49cf7855d74d1629279fbfbaf2fb22adf5abd8382ae6e5b37b844deec9ad528a4d1f7dabda83867ca9a17d98cd28a2fd574017ac717128aa44379
java.security.MessageDigest
707876
Adobe Acrobat Document
1.7
DIAS
62
DIAS tentative identification
main.pdf
local
1491214186761
0
SHA-512
5938a1f761bc06f1b80cd17969d27de1777577588775cccf15749a4e5a8219045916daac42ce785e032b3943f3d1af56044a1f1c8919b737cd814c60a215f9ee
java.security.MessageDigest
21997
not checked
main.xml
free
00001
The Authors
KB-agent-id
1
supplier
KB-owner-id
00001
KB-agent-id
1
Elsevier
organization
The Authors
ingestion
2017-04-03T10:41:49.407+02:00
Connector
software
Digitaal Magazijn release 1.5
ejournals_esp_1
streamprofile
ingestion2017-04-03T12:36:21.364+01:00Generic IngestsoftwareDigitaal Magazijn release 1.5